PMID- 33693491
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20210920
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 156
IP  - 3
DP  - 2021 Aug 4
TI  - "Indeterminate" UroVysion Fluorescence In Situ Hybridization Results.
PG  - 427-432
LID - 10.1093/ajcp/aqaa254 [doi]
AB  - OBJECTIVES: UroVysion cases with one to three abnormal cells that do not meet the 
      threshold for positivity may be better classified as "indeterminate." The aim of 
      this study is to determine the incidence and clinical significance of these 
      indeterminate UroVysion results. METHODS: The UroVysion fluorescence in situ 
      hybridization (FISH) results over a 4-year period in our institution were 
      retrospectively analyzed. Follow-up of the initial UroVysion cases, including 
      urine cytology or bladder biopsy performed within 12 months of the initial 
      diagnosis of the result, was obtained from pathology reports. RESULTS: A 
      significant fraction (178 of 1,907, 9.3%) of the UroVysion cases had 
      indeterminate results. Overall, the subsequent malignancy rate of the group with 
      indeterminate UroVysion results (14 of 59, 23.7%) was higher than the group with 
      normal results (48 of 319, 15.0%), although the difference was not significant 
      (P = .124). For patients without a history of urinary tract neoplasm, the 
      subsequent malignancy rate in the group with indeterminate results (7 of 18, 
      38.9%) was significantly higher than the group with normal results (16 of 103, 
      15.5%) (P = .044). CONCLUSIONS: Our results support that indeterminate UroVysion 
      FISH result may warrant closer clinical follow-up in patients without a history 
      of urinary tract neoplasm. We suggest reporting these cases as "aneusomy of 
      undetermined significance."
CI  - (c) American Society for Clinical Pathology, 2021. All rights reserved. For 
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Xu, Jing
AU  - Xu J
AD  - Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
FAU - Westfall, Danielle E
AU  - Westfall DE
AD  - Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
FAU - Lopategui, Jean R
AU  - Lopategui JR
AD  - Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
SB  - IM
MH  - Cytodiagnosis
MH  - Fluorescence
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Pathology, Molecular
MH  - Retrospective Studies
MH  - Urinary Bladder Neoplasms/*diagnosis/pathology
OTO - NOTNLM
OT  - Molecular diagnostics
OT  - Urinary tract neoplasm
OT  - UroVysion
EDAT- 2021/03/12 06:00
MHDA- 2021/09/21 06:00
CRDT- 2021/03/11 06:44
PHST- 2021/03/12 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
PHST- 2021/03/11 06:44 [entrez]
AID - 6161213 [pii]
AID - 10.1093/ajcp/aqaa254 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2021 Aug 4;156(3):427-432. doi: 10.1093/ajcp/aqaa254.